Percheron Therapeutics (ASX:PER) submitted a non-binding proposal to a pharmaceutical company to in-license a new drug development program focusing on a rare neurological disease, according to a Monday Australian bourse filing.
The proposal remains subject to further negotiations, as well as the execution of a definitive agreement, the filing said.
The firm estimated that at this stage it would take eight to 12 weeks to negotiate and sign a definitive agreement.
It plans to continue to evaluate alternative opportunities in parallel to the proposal.
The firm's shares jumped 8% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.